LIVER-R is a research study to understand how well a medicine called durvalumab works for people with liver and bile duct cancers. These cancers are known as hepatobiliary cancers. This study is observational, which means doctors will watch and record information about patients without changing their regular treatment. The study will take place in many countries and involve around 2,500 adults already receiving durvalumab as part of their normal care or through an early access program (EAP).

Doctors will collect data directly from patients during visits and from their medical records. They will note things like how long patients survive, any significant health events, and details about their treatments. The study will last up to 3 years for liver cancer patients and 2 years for bile duct cancer patients.

• The study includes patients who are already receiving durvalumab.
• It will last up to 3 years for liver cancer and 2 years for bile duct cancer.
• Participation is only for those not in other experimental treatment trials.